Cerveau Health Technologies

Cerveau Health Technologies is a biotechnology company focused on developing and commercializing diagnostic imaging agents for neurodegenerative diseases. The company's lead candidate is MK-6240, a high-affinity positron emission tomography (PET) imaging agent designed to detect the density and distribution of aggregated Tau protein neurofibrillary tangles in the brain. By providing tools to visualize the progression of Alzheimer's disease and other tauopathies, Cerveau supports pharmaceutical partners in clinical drug development and aims to improve patient management. The company operates through a global network of production sites and collaborations with academic and industry leaders.